Abstract
The T-cell activation-Ag CD26 possesses dipeptidyl peptidase IV (DPP IV) enzymatic activity. Costimulatory efficacy and immunocompetence are associated with the enzymatic activity. Goals: In models of experimental cardiac allograft transplantation (HTx), we analyzed the role of CD26/DPP IV during organ rejection. Also, we investigated CD26 enzymatic and cellular expression in human recipients of kidney transplants (Tx). Material and Methods: Heterotopic HTx in rats, models of acute and accelerated rejection. Monitoring of DPP IV serum levels and humoral immunity. Propro-diphenyl phosphonate was employed to inhibit DPP IV activity during rejection. In a prospective study, surface expression of CD26, 3, 4, 8, 45, 122 and ADA on PBL and DPP IV serum activity were measured in kidney recipients for 24 months post-transplantation. Results: Acute rejection was associated with increased serum DPP IV activity (p<0.005). Specific inhibition abrogated acute (p<0.0001) and accelerated (p<0.01) rejection, impairing cytotoxicity and allospecific Ig-synthesis. Kidney recipients displayed a significant drop in CD26 expression on PBL for up to 18 months postoperatively (p<0.001). CD4, 8, 45, 122 and ADA expression kinetics were only briefly affected. DPP IV enzymic activity stayed depressed for at least 12 months (p<0.001). Conclusion: CD26/DPP IV is pivotal in T-cell mediated immune responses toward allo-Ag. In clinical transplantation, engraftment/immunosuppression are reflected by CD26 cellular and enzymatic expression posttransplantation and may serve as an indicator for immunomodulation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Morimoto, C., and Schlossman, S. F., 1994. CD26 a key costimulatory molecule on CD4 memory cells. The Immunologist 2/1:4–7.
De Meester, I., Korom, S., Van Damme, J., and Scharpsé, S., 1999. CD26, let it cut or cut it down. Immunology Today 20:367–375.
Tanaka, T., Kameoka, J., Yaron, A., Schlossman, S.F., Morimoto, C., 1993. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 90:4586–4590.
Tanaka, T., Duke-Cohan, J. S., Kameoka, J., et al. 1994. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 91:3082–3086.
Scharpé, S., De Meester, I., Vanhoof, G., et al. 1990. Serum dipeptidyl peptidase IV activity in transplant recipients. Clin Chem 36:984.
Sanda, M.G., Pierson, R., Smith, C., and Rose, E., 1989. Serum dipeptidyl peptidase IV in cardiac transplant recipients. Transplant Proc 21:2525–2526.
Belyaev, A., Borloo, M., Augustyns, K., et al. 1995. A new synthetic method for proline diphenyl phosphonates. Tetrahedron Letters 36:3755–3758.
Lambeir, A.M., Borloo, M., De Meester, I., et. al. 1996. Dipeptidyl-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl-peptidase IV. Biochimica Biophys Acta 1290:76–82.
Korom, S., De Meester, I., Stadlbauer, T.H.W., et al. 1997. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 63:1495–1500.
Scharpé, S., De Meester, I., Vanhoof, G., Hendriks, D., van Sande, M., Van Camp, K., and Yaron, A., 1988. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphtylamine. Clinical Chemistry 34:2299–2301.
Binder, J., Lehmann, M., Graser, E., Hancock, W.W., et al., 1996. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 61:804–811.
Fleischer, B., 1987. A novel pathway of human T cell activation via a 103 kD T cell activationmolecule. J Immunol 138:1346–1350.
Dang, N.H., Hafler, D., Schlossman, S.F., and Breitmeyer, J., 1990. FcR-mediated cross-linking of Tal (CDw26) induces human T lymphocyte activation. CellImmunol 125:42–57.
Dang, N.H., Torimoto, Y., Sugita, K., Daley, J.F., Schow, P., Prado, C., Schlossman, S.F., and Morimoro, C., 1990. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol 145:3963–3971.
Schön, E., Jahn, S., Kiessig, S.T., et al. 1987. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 17:1821–1826.
Flentke, G.R., Muñoz, E., Huber, B.T., Plaut, A.G., Kettner, C.A., and Bachovchin, W., 1991. Inhibition of dipeptidyl peptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci USA 88:1556–1559.
Kubota, T., Iizuka, H., Bachovchin, W.W., and Stollar, B.D., 1994. Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin Exp Immunol 96:292–296.
Bednarczyk, J., Caroll, S.M., Marin, C., and McIntyre, B., 1991. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 46:206–218.
Korom, S., De Meester, I., Schmidbauer, G., et al. 1999. Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity. Transplant Proceedings, 31:873.
Korom, S., De Meester, I., Maas, E., et al., 2002. CD26 expression and enzymatic activity in recipients of kidney allografts. Transplant Proceedings, 34:1753–1754.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Korom, S., De Meester, I., Belyaev, A., Schmidbauer, G., Schwemmle, K. (2004). CD26/DPP IV in Experimental and Clinical Organ Transplantation. In: Back, N., Cohen, I.R., Kritchevsky, D., Lajtha, A., Paoletti, R. (eds) Dipeptidyl Aminopeptidases in Health and Disease. Advances in Experimental Medicine and Biology, vol 524. Springer, Boston, MA. https://doi.org/10.1007/0-306-47920-6_17
Download citation
DOI: https://doi.org/10.1007/0-306-47920-6_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-47717-1
Online ISBN: 978-0-306-47920-5
eBook Packages: Springer Book Archive